Association of musculoskeletal pain with the achievement of treatment targets for type 2 diabetes among primary care patients. Issue 4 (August 2022)

• Record Type: Journal Article
• Authors: Heikkala, Eveliina; Hagnäs, Maria; Jokelainen, Jari; Karppinen, Jaro; Ferreira, Paulo; Ferreira, Manuela L.; Mikkola, Ilona
• Is Part Of: Primary care diabetes. Volume 16:Issue 4(2022)
• Page Start: 531
• Page End: 536
• Publication Date: 2022-08
• Subjects: Type 2 diabetes -- Musculoskeletal pain -- Treatment target -- Primary care; Diabetes -- Periodicals; 616.462
• DOI: 10.1016/j.pcd.2022.04.006
• Languages: English
• ISSNs: 1751-9918

Abstract

Abstract: Aims: To assess the association of diagnosed musculoskeletal (MS) pain (low back, neck, shoulder, and knee pain; and the number of pain sites) with the achievement of targets for glycosylated haemoglobin A1c (HbA1c), low-density-lipoprotein cholesterol (LDL), and systolic blood pressure (SBP) among primary care patients with type 2 diabetes (T2D). Methods: The cross-sectional study population consisted of 3478 patients with a registry-based T2D diagnosis and available registry-based data on MS pain diagnoses, covariates, and outcomes between 2016 and 2019. Logistic regression analysis was used to evaluate the study aims. Results: Overall, 22% had at least one of the four types of MS pain, and 73%, 57%, and 51% achieved the treatment targets of HbA1c, LDL, and SBP, respectively. T2D patients with or without MS pain did not differ in their achievement of T2D treatment goals. Of pain locations, low back pain was associated with higher rates of achievement of the LDL target (OR 1.29, 95% CI 1.01–1.65), but the association was attenuated in the adjusted model. Conclusions: MS pain was relatively prevalent among primary care patients with T2D, but did not influence the achievement of T2D treatment goals. Highlights: Musculoskeletal pain (MS) is relatively prevalent among elderly primary care patients with type 2 diabetes. Knee is the most common MS pain location. MS pain does not influence the achievement of type 2 diabetes treatment targets.